Pimecrolimus cream in the management of patients with atopic eczema by Spergel, Jonathan M
© 2009 Spergel, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical, Cosmetic and Investigational Dermatology 2009:2 85–93
Clinical, Cosmetic and Investigational Dermatology
85
r e v I e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Pimecrolimus cream in the management  
of patients with atopic eczema
Jonathan M Spergel
Division of Allergy and Immunology, 
The Children’s Hospital of Philadelphia 
Department of Pediatrics, University 
of Pennsylvania School of Medicine
Correspondence: Jonathan M Spergel 
Division of Allergy and Immunology,  
The Children’s Hospital of Philadelphia, 
wood Center, 34th Street and Civic Ctr 
Blvd, Philadelphia, PA 19104, USA 
Tel +1 215 590 2549 
Fax +1 215 590 4529 
email spergel@email.chop.edu
Abstract: Atopic eczema is a common pediatric skin disorder. This review examines the use 
of pimecrolimus cream in the treatment of acute and chronic stages of the disease. The standard 
therapy is the treatment of acute flares with topical medications including pimecrolimus. The use 
of pimecrolimus cream for the first sign and symptoms of atopic eczema reduces the occurrence 
of flares as defined by the need for topical corticosteroids. The side effects of pimecrolimus 
cream are mild without any increase of infections or systemic immune suppression.
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Introduction
Atopic eczema (AE) (atopic dermatitis) is a common, inflammatory skin disorder that 
adversely affects many aspects of patients’ lives. The prevalence of AE among children 
is 18.1% in Italy, 20.6% in Norway, 14.4% in Denmark, and 17.2% in the United 
States1–4 making it one of the most common pediatric skin disease. The International 
Study of Asthma and Allergies in Childhood (ISAAC) Phase 3 study found that AE 
prevalence was stabilizing or decreasing in developed countries (New Zealand, Ireland, 
Sweden, Germany, United Kingdom) but still increasing in developing countries 
(Mexico, Chile, Kenya, Algeria, and 7 countries in Southeast Asia).5
AE is also the start of the Atopic March, which is the natural progression of 
allergies from the skin to the nose and lung. Approximately 30% to 50% of children 
with AE will develop asthma and 75% will develop allergic rhinitis.6 Environmental 
and genetic evidence points to a defect in the skin barrier as a major contributor to the 
onset of AE and progression of the atopic march. The defect in the epithelial barrier 
of the skin may in part be due to mutations in the filaggrin gene, a key protein in the 
formation of the skin barrier. It is now hypothesized that improvement in the skin 
barrier will prevent the progression of AE to asthma.7,8
Clinical presentation of AE
AE typically presents in the first years of life with greater than 90% diagnosed in the 
first 5 years. AE is a clinical diagnosis and not a laboratory or histological diagnosis 
based on classic criteria of major and minor criteria (Tables 1 and 2). The classic 
distribution of these lesions varies with age: in infancy through early childhood, face, 
extensor and exposed skin surfaces are involved. In older children, flexural surfaces 
are more characteristically affected. In adults, the face, neck, chest, hands, and feet 
areas can also be affected. Other hallmarks include xerosis (dry skin) and pruritus, Clinical, Cosmetic and Investigational Dermatology 2009:2 86
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resulting in a vicious itch-scratch cycle. Excoriations may be 
apparent and, in the chronic state, result in lichenification of 
the skin. Recurrent skin infections by bacteria, viruses, and 
dermatophytes may also occur.
Pathogenesis of AE
Although the etiology of the disease is incompletely 
understood, AE is considered the product of complex inter-
actions among the host’s environment, susceptibility genes, 
skin barrier dysfunction, and local and systemic immune sys-
tem dysregulation, extensively reviewed by Bieber.9 Briefly, 
breakdown of the skin barrier is recognized to be important in 
the development of AE; however, it is debated whether this 
event is secondary to the inflammatory response to irritants 
and allergens (“inside-outside hypothesis”) or whether the 
barrier damage itself drives disease activity (“outside-inside 
hypothesis”).10 Clinical data have indicated that the extent 
of disease activity is correlated with skin barrier function.11
The skin interaction with the underlying immune system 
is the next key step in the pathogenesis of AE. For the start 
of the allergic response in AE, allergen-specific IgE binds to 
mast cells in the skin through the high-affinity Fc receptor I 
(FcεRI), resulting in mast-cell degranulation and the release of 
inflammatory mediators. During this process, the production 
of IgE by B cells depends on the support of T-helper 2 
(Th2) cells.12 The initial, acute phase of AE is thought to 
be dominated by Th2 cytokines, whereas the chronic stage 
is thought to be T-helper 1 (Th1)-dominated;13–15 however, 
there also is evidence that regulatory T (Treg) cells may 
play a role in the latter stage16 in the control of the chronic 
inflammation.
Triggers of AE
Triggers can vary among patients, but commonly include 
detergents, soaps, toiletries containing alcohol or astringents, 
assorted chemicals, infectious agents, aeroallergens (eg, dust 
mites, animal dander), and certain foods.17 Both food and 
environmental allergens have been implicated as offending 
agents in AE, but the incidence is variable among pediatric 
and adult populations. In adults, less than 2% of AE patients 
have a food allergy as an exacerbating factor.18 In contrast, 
10% to 33% of severe AE cases have an associated food 
allergy in infants and young children.19,20 The more severe AE 
is more likely that a food allergy exists and is a contributing 
factor. Thus, the diagnosis of a food allergy should be 
considered in young children who have generalized or severe 
AE, or those who have recalcitrant disease despite aggressive 
therapy. Milk, soy, egg, peanut, and wheat accounted for 90% 
of food allergies implicated in AE.21 Elimination of offending 
foods can result in clinical improvement of AE.22 In addition 
to foods, environmental aeroallergens can also be signifi-
cant triggers in AE. Aeroallergens may be more important 
in older children and adults, as these populations are more 
likely to have become sensitized. More than 85% of adults 
with AE have evidence of IgE-mediated hypersensitivity to 
environmental allergens.23 In children with AE, IgE-mediated 
aeroallergen sensitization first appears between the ages of 
2 to 5 years, and predominates over food allergies by age 5.24 
However, in many patients, aeroallergen sensitization is 
only relevant for allergic rhinoconjunctivitis and not atopic 
dermatitis. Nevertheless, in a subset of atopic dermatitis 
patients inhalational or topical exposures to aeroallergens 
can exacerbate AE.25,26
Treatment of AE
The basic treatment of AE is good skin care and avoidance of 
the allergens, triggers and irritants. Basic skin care involves 
hydration and moisturization of the skin. The review will focus 
Table 1 Atopic eczema diagnostic criteria63
Major features
  1.  Pruritis
  2.  Typical morphology and distribution:
	 a.	 Flexural	lichenification	or	linearity	in	adults
  b.  Facial and extensor involvement in infant and children
  3.  Chronic or chronically relapsing dermatitis
 4.  Personal or family history of atopy (asthma, allergic rhinitis, atopic eczema)
Minor features
  1.  Xerosis
  2.  Ichthyosis/palmar hyperlinearity/keratosis pilaris
  3.  Immediate (type I) skin test reactivity
  4.  elevated serum Ige
  5.  early age of onset
  6.  Tendency toward cutaneous infection/impaired cell-mediated immunity
	 7.	 Tendency	toward	nonspecific	hand	or	foot	dermatitis
  8.  Nipple eczema
  9.  Cheilitis
10.  recurrent conjunctivitis
11.  Dennie-Morgan infraorbital fold
12.  Keratoconus
13.  Anterior subcapsular cataracts
14.  Orbital darkening
15.  Facial pallor/facial erythema
16.  Pityriasis alba
17.  Anterior neck folds
18.  Itch when sweating
19.  Intolerance to wool and lipid solvents
20.  Perifollicular accentuation
21.  Food allergy
22.	 Course	influenced	by	environmental/emotional	factors
23.  white dermatographism/delayed blanchClinical, Cosmetic and Investigational Dermatology 2009:2 87
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on the use of anti-inflammatory medication in the treatment 
of AE. During an acute infection, appropriate antibiotics can 
be used to treat the infectious trigger. However, the natural 
history of eczema has intermittent flares with erythema and 
increased pruritus. The treatment of flares involves the use of 
anti-inflammatory agents. The classic agent is topical corti-
costeroids (TCS). TCSs have been the predominant first-line 
treatment for moderate to severe AE for several decades.27,28 
The potencies of TCSs range from very mild to very strong, 
and the choice among formulations is tailored to the severity 
of the disease and exacerbation and the area of the body that 
is affected. Cutaneous, potency-related side effects (eg, skin 
atrophy, striae, telangiectasias, acne rosacea, and perioral 
dermatitis) limit the long-term use of these agents.29 However, 
their long-term application can be problematic in children 
because of the potential for side effects, particularly skin 
atrophy and hypothalamic–pituitary–adrenal (HPA)–axis 
suppression with extensive use of high-potency topical 
corticosteroids.30,31 Another potential problem with TCS is 
compliance, as many patients and parents express concerns 
regarding the prolonged use of these agents.32
Therefore, in the last 10 years, two non-steroidal 
anti-inflammatory therapies have been developed and 
approved in the form of two topical calcineurin inhibitors–
pimecrolimus cream (Elidel®, SDZ ASM 981; Novartis) and 
tacrolimus ointment (Protopic®, FK 506; Astellas Pharma). 
Pimecrolimus is available as a 1% cream and is approved in 
the US and Europe for the treatment of mild to moderate AE, 
in children over 2 years of age; in approximately 40 countries, 
pimecrolimus is also available for the treatment of infants 
(3 to 23 months of age).33 Tacrolimus ointment is approved 
for the treatment of moderate to severe AE and is available 
as an ointment in two concentrations: 0.03% and 0.1% for the 
treatment of adults, and 0.03% for the treatment of children 
aged 2 to 15 years.34
Both compounds bind with high affinity to the 
macrophilin-12 receptor and inhibit calcineurin, a 
calcium-dependent phosphatase that is required for activation 
of the nuclear factor of activated T cells (NF-AT). The 
inactive form of nuclear factor of activated T cells cannot 
enter the nucleus. Therefore, via blockage of NF-AT, these 
agents inhibit the inflammatory cascade produced pathologic 
T cells inhibiting expression of cytokines (IL-2, IL-4, IL-5, 
IL-10 and interferon-gamma).35
Pimecrolimus, in addition to preventing expression of 
pro-inflammatory cytokines and the proliferation of T cells, 
also inhibits activation of co-receptors required for T-cell 
activation and prevents the release of inflammatory mediators 
from mast cells. Unlike TCSs and tacrolimus, pimecrolimus 
does not induce apoptosis in Langerhans cells.35,36
Clinical evidence
More than 3000 patients were treated with pimecrolimus for 
up to 2 years in clinical trials.37,38 in both adult and pediatric 
populations. The trials were designed in two basic schemes, 
one treating acute flares in 6-week double-blind placebo-
control study and the second scheme was the treatment at the 
first sign of inflammation in a pro-active fashion to prevent 
acute flares of atopic dermatitis.39 Improvement in AE was 
measured by three basic methods, Eczema Area Severity 
Index (EASI), Investigators’ Global Assessment (IGA) and 
reduction of flares needing topical corticosteroids. The EASI 
is a validated composite score comprising severity ratings 
of erythema, oedema/induration/papulation, excoriations 
and lichenification weighted according to the estimated 
percentage of affected body surface area (BSA) of each 
body region. For each body region (head/neck, upper limbs, 
trunk and lower limbs), an affected area score of 0 to 6 was 
assigned for the percentage of affected BSA (0% to 100%). 
The individual ratings for erythema, edema/induration/
papulation, excoriations and lichenification were then added 
(0 to 3 for each of the four symptoms) before the sum of the 
individual symptoms (maximum = 12) was multiplied by 
the affected area score (maximum = 6) to give a maximum 
of 72. The head/neck subtotal was multiplied by 0.1, the 
upper limb subtotal by 0.2, the trunk subtotal by 0.3, and the 
lower limb subtotal by 0.4 before being summed (maximum 
EASI = 72).40 The IGA is a physician assigned clinical score 
that ranges from 0 to 5 (none to very severe) on the physician 
determination of AE severity.
The pediatric trials have shown short-term efficacy in 
patients randomized 2:1 to 6 week trial of pimecrolimus 
treatment or vehicle followed by 20-week open label extension 
in children young as 3 months of age (Table 3). In the trial 
of 403 children and young adults (aged 1 to 17 years with 
Table 2 Atopic eczema in infancy diagnostic criteria63
Major features
1.  Pruritic dermatitis
2.	 Typical	facial	or	extensor	eczematous	or	lichenified	dermatitis
3.  Family history of atopy (asthma, allergic rhinitis, atopic eczema)
Minor features
1.  Xerosis/ichthyosis/hyperlinear palms
2.  Perifollicular accentuation
3.  Chronic scalp scaling
4.	 Peri-auricular	fissuresClinical, Cosmetic and Investigational Dermatology 2009:2 88
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an IGA score at baseline of 2 or 3 [mild or moderate AD]),41 
35% of the children treated with pimecrolimus were clear 
or almost clear of AE at 6 weeks, compared 18% children 
treated with the vehicle (p  0.05). In the same trial, 60% 
of pimecrolimus-treated patients showed at least a one-point 
reduction in the IGA score by 6 weeks compared to 33% of 
vehicle-treated patients.41 In the infant trial of 186 patients 
with a baseline IGA score of 2 or 3 (mild or moderate AE),39 
in addition to the other two pimecrolimus-treated patients 
showed significant improvement in IGA scores compared 
to placebo at the end of 6 week blinded trial. Similarly in 
another infant trial, 55% of the pimecrolimus-treated patients 
were almost or clear (IGA = 1 or 0) compared to 24% in 
vehicle group.42 The adult trials were of similar design with 
130 adults and open labeled study of 947 of patients from 
3 months to 81 years of age (Table 4).43–45 In the adult trial, 
IGA scores also significantly improved in pimecrolimus 
group compared to placebo.
Pruritus
One of the clinical features of AE is intense pruritus. AE is 
often called the itchy skin that rashes. Pimecrolimus cream 
1% showed improvement in pruritus by the eighth day in the 
infant in 70% of the children compared to 37% of the children 
treated with vehicle (p  0.001). A similar effect was noted 
in children and adolescents, with 44% of pimecrolimus-
treated patients reporting no (0) or mild (1) pruritus at Day 8, 
compared with 26% of vehicle-treated patients (p  0.001).46 
In the adult trial of 130 patients, self-assessed pruritus 
severity scores had improved by at least 1 point (4-point 
scale of 0 to 3) in 45% of patients treated with pimecrolimus 
compared with 17% of those using vehicle (p = 0.0016).47 
A significant treatment effect was also observed shortly 
after initiating pimecrolimus treatment even in a group of 
eczema patients with moderate to severe pruritus. Within 
2 days, 42% of pimecrolimus-treated compared with 27% of 
vehicle-treated patients scored their pruritus as mild or absent 
(pruritus score of 0 or 1; p = 0.040), and these treatment 
differences were maintained throughout the study.48
Erythema/inflammation
The other cardinal features of AE are erythema and 
inflammation. In one study of moderate AE in the adults, 
signs and symptoms improved progressively throughout the 
first 6 weeks of treatment, with a 33% reduction in EASI 
scores after the first 7 days and eczema score improved by 
69.8% at the end of 6 weeks. In comparison, the patients 
treated with vehicle group had worsening eczema evidenced 
by an increase by 3.8% after 1 week and at Week 6 at 15.9% 
(Figure 1).47
In the pediatric trials, improvement in eczema severity 
is also noted by changes in EASI scores. Pimecrolimus-
treated patients with improvement within 1 week continued 
to improve during the length of the study (Figure 2). Young 
children and adolescents showed improvements for each 
measure: for example, erythema; 61% of pimecrolimus-treated 
Table 3 Pimecrolimus pediatric trials
Author No patients Study design Duration Measurement
Eichenfield41 403 randomized/open label 6 weeks/20 weeks eASI, IGA
Ho42 186 randomized/open Label 6 weeks/20 weeks eASI, IGA
Kapp39 251 randomized 1 year Flares, eASI, IGA
Papp45 81 randomized/open label 1 year/1 year eASI, IGA, Flare
wahn44 713 randomized 1 year EASI,	flare
Abbreviations: eASI, eczema Area Severity Index; IGA, Investigators’ Global Assessment, IGA.
Table 4 Pimecrolimus adult trials
Author No patients Study design Duration Measurement
Gollnick64 266 randomized/placebo 26 weeks Flare, IGA
Meurer65 192 randomized/placebo 24 weeks Flares, IGA
Meurer47 130 randomized/placebo 24 weeks Flares, IGA
Luger59 658 randomized pimecrolimus/TCS 52 weeks Safety
Kaufmann48 198 randomized/placebo 7 days Pruritus
Abbreviations: IGA, Investigators’ Global Assessment;   TCS, topical corticosteroids.Clinical, Cosmetic and Investigational Dermatology 2009:2 89
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versus 37% of vehicle-treated at 6 weeks.41 The improvement 
in eczema severity occurred in all age groups, including 
infants. Pimecrolimus reduced the signs of inflammation 
(erythema and infiltration) by 8 days in the infant trial. 61% 
of the patients treated with pimecrolimus had no or only 
mild erythema on all body areas, compared with 27% of 
patients treated with vehicle (p  0.001). For infiltration, 
67% patients treated with pimecrolimus had no or only mild 
symptoms on all body areas, compared with 40% in the 
vehicle group in the same infant trial.42
As mentioned earlier, patients also had short-term 
improvement in IGA scores. Long-term improvement was 
noted in a trial of 947 patients in a 1-year open-labeled 
study, aged from 3 months to 81 years; improvements in 
IGA were noted by 8 days in the total population.43,49 In the 
same study, 394 patients enrolled with moderate disease; 
18% improved to IGA of 0 or 1 by 1 week, rising to 42% at 
day 168. With a similar study of 262 children with moderate 
eczema (IGA = 3) at baseline, 34.7% were clear or almost 
clear of eczema after 1 year of open-labeled treatment.44 For 
the 87 children with severe/very severe AE (IGA = 4/5) at 
baseline, 18.4% were clear or almost clear of AE at 1 year, 
19.5% had mild eczema (IGA = 2) and 31% improved to 
moderate disease (IGA = 3). These results indicate that 
all patients within varying severity can improve with 
pimecrolimus treatment.
Prevention of flares
AE is a chronic disease with periods of relapse and flares. 
Several trials examined the use of pimecrolimus form the 
start of symptoms to prevent flares in year-long trials in and 
children and adolescents. The use of pimecrolimus creams 
decreased over the year in both trials, indicating overall 
control with pimecrolimus. The total body surface area 
affected by eczema decreased over a year-long open-label 
trial from 24% to 7% in children/adolescent trial.50 The time 
to first flare was substantial longer in the pimecrolimus-
treated group compared to the vehicle treated group. In fact, 
61% of children and adolescents in the pimecrolimus group 
were flare-free for 6 months and 51% were flare-free for 
12 months of treatment, which is significantly more than the 
vehicle-treated group, as only 34% of patients in the control 
group at 6 months and 28% at 12 months were flare-free.44 For 
the infants and toddlers, 68% were flare-free for 6 months of 
treatment, and 57% were flare-free for 12 months of treatment 
in the pimecrolimus-treated group. In contrast, in the control 
group, 30% and 28% of patients completed 6 and 12 months 
of treatment without flares, respectively.39 In similar studies 
with pimecrolimus in adults, the prevention of flares can also 
be observed. In an identical designed trial but of 24 weeks’ 
duration, more adults patients with moderate AE treated 
with pimecrolimus remained in remission and experienced 
no major flares compared to vehicle group (pimecrolimus/
vehicle: 59.7% vs 22.1%, p = 0.001).47
Long-term treatment of AE
The alternative strategy to prevent flares is to use medications 
in a preventative fashion, as in in asthma, another atopic 
disease. Several recent trials have tried this strategy of medi-
cation on a regular basis 2 to 4 times a week to prevent flares 
even before the start of symptoms. Studies have examined 
both the use of topical steroids (fluticasone) or tacrolimus 
ointment three times a week to reduce the incidence of 
flares (Table 5). 348 patients (231 children, 117 adults) were 
randomized at a 2:1 ratio to either intermittent fluticasone 
propionate (FP) or vehicle, once daily 4 days per week for 
4 weeks followed by once daily 2 days per week for 16 weeks. 
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The patients on the active therapy were 7.7 times less likely to 
have a AE flare.51 A second trial of similar design examined 
FP 2 days week compared to placebo for prevention of flares 
in 295 patients (12 to 65 years of age). The time to first relapse 
was 6 weeks for placebo compared to 16 weeks for FP.52 
In the Breneman study with tacrolimus three times a week, 
197 adult patients were randomized to tacrolimus (125) and 
vehicle (72). The tacrolimus had more flare-free days (177 for 
tacrolimus and 134 for vehicle, p = 0.003). Also, the time for 
first relapse was 169 days for tacrolimus and 43 for vehicle, 
significantly better for the active therapy (p = 0.037).53 
A similar study in pediatrics showed a significant effect of 
105 patients using tacrolimus three times a week compared 
to placebo after 16-week open-label run-in with 0.03% 
tacrolimus ointment. The patients on tacrolimus arm had 
significantly more disease-free days and longer time to first 
relapse.54 The third tacrolimus study examined 224 adults 
randomized to either tacrolimus or placebo twice a week to 
prevent flares. The active therapy (tacrolimus) increased the 
time to first flare from 15 to 142 days compared to placebo 
treatment.55 The fourth study examined 250 children random-
ized to either tacrolimus or placebo twice a week to prevent 
flares. Similar to adult study, the active therapy (tacrolimus) 
increased the time to first flare from 38 days to 178 days. 
Also, the number of flares decreased in tacrolimus group 
compared to placebo.56
Safety
For the use of any medications, the issue of safety is important 
(both local and systemic). For topical calcineurin inhibitors, 
the local side effects would be confined to the skin. During 
randomized trials using pimecrolimus, the most commonly 
reported form of application-site reaction in children and 
adults was a sensation of burning at the application site. 
Interestingly, it was reported at a similar rate in both vehicle- 
and pimecrolimus-treated children (10.4% of pimecrolimus-
treated versus 12.5% of vehicle-treated patients).41
For the systemic side effects, pimecrolimus would need to 
be absorbed at high levels. However, the use of pimecrolimus 
cream in AE does not lead to any significant levels in the 
circulating blood system. In pharmacokinetic studies of 
children with moderate to severe AE with up to 92% BSA 
affected, 67% of samples had pimecrolimus blood concen-
trations below 0.5 ng/mL and 97% of blood concentrations 
were in the range of 0.5 to 2.0 ng/mL. Also, for rat, pig, and 
human skin, pimecrolimus demonstrated a 9- to 10-fold 
lower permeation through skin in vitro than tacrolimus when 
comparing identical solutions of both compounds.36 Patients 
treated with pimecrolimus in the AD trial have normal T and 
B cell function as evidenced by response to vaccination and 
delayed hypersensitivity response. Cell-mediated, delayed-type 
hypersensitivity (DTH) reaction against a range of antigens 
is a common method of assessing immunocompetence. DTH 
testing was used to test immune function in one study of 
pimecrolimus cream 1% with a total of 112 subjects who 
completed 1 year of treatment (82 pimecrolimus cream 1%; 
30 vehicle).44 Pimecrolimus had no effect on DTH testing with 
similar response to that of the placebo group.
Skin infections are another concern. Patients with AE 
are more prone to skin infections: Staphylococcus aureus 
and viral infections, including herpes simplex, herpes zoster, 
Epstein-Barr virus, molluscum contagiosum, and human 
papilloma virus.57,58 Skin infections were investigated in 
1-year study comparing pimecrolimus and triamcinolone 
acetonide 0.1% cream in 658 adults.59 Pimecrolimus was 
not associated with an increase in bacterial or fungal skin 
infections, or in herpes simplex or herpes zoster infections 
compared to triamcinolone. In the pediatric trials, there 
were no significant differences in overall incidence of skin 
infections after pimecrolimus treatment in infants or children. 
In a 2-year open-label trial, the frequency of skin infections 
did not change over time, as the incidence of skin infections 
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was comparable in the first and second years of treatment. 
Compared with control treatments, the incidence of all bacte-
rial and viral infections with pimecrolimus in infants treated 
for more than 1 year was low.60,61 Overall, pimecrolimus 
cream has demonstrated low systemic absorption and a low 
incidence of systemic adverse events in children and adults.
Pimecrolimus was issued a black box warning in 2006 due 
to concerns about incidence of lymphoma. This warning was 
based on hypothetical concerns about pimecrolimus caus-
ing Epstein-Barr virus induced lymphoproliferation disease 
(lymphoma) or skin cancer. This warning was reviewed by 
many academic allergy and dermatology societies with the 
feeling that it was not warranted. The joint task force from 
the American Academy of Allergy Asthma and Immunology 
and American College of Allergy Asthma and Immunology 
found that the risk-benefit ratio of topical pimecrolimus and 
tacrolimus are similar to that of most conventional therapies 
for the treatment of chronic relapsing eczema. The panel 
concluded that
1.  Lymphoma formation is generally associated with high 
dose and sustained systemic exposure to pimecrolimus 
and tacrolimus.
2.  The reported cases of lymphoma from topical pimecro-
limus and tacrolimus are not consistent with lymphomas 
observed with systemic immunomodulator therapy.
3.  The actual rate of lymphoma formation reported to date 
for topical calcineurin inhibitors is lower than predicted 
in the general population.
In large-scale pharmacologic database studies of 
over 250,000 patients, no increase in the incidence with 
pimecrolimus was noted for lymphoma.62 The risk of 
lymphoma does not seem to be an issue for patient using 
pimecrolimus cream.
Conclusion
Pimecrolimus cream is a safe and effective therapy for the 
treatment of atopic dermatitis. One of the key components 
of AE is itch and inflammation. Both elements are relieved 
within 1 week of pimecrolimus treatment. One of the novel 
potential uses of pimecrolimus cream in the treatment of AE is 
the use of proactive therapy. The use of pimecrolimus cream 
at the first signs and symptoms of AE flare reduces the need 
for topical steroids. Finally, pimecrolimus cream appears to 
be safe in both long- and short-term trials with equivalent or 
superior safety profile to topical corticosteroids.
Disclosures
The author discloses no conflicts of interest.
References
  1.  Peroni DG, Piacentini GL, Bodini A, Rigotti E, Pigozzi R, Boner AL. 
Prevalence and risk factors for atopic dermatitis in preschool children. 
Br J Dermatol. 2008;158(3):539–543.
  2.  Smidesang I, Saunes M, Storro O, et al. Atopic dermatitis among 2-year 
olds; high prevalence, but predominantly mild disease–the PACT study, 
Norway. Pediatr Dermatol. 2008;25(1):13–18.
  3.  Kjaer HF, Eller E, Host A, Andersen KE, Bindslev-Jensen C. The 
prevalence of allergic diseases in an unselected group of 6-year-old 
children. The DARC birth cohort study. Pediatr Allergy Immunol. 
2008;19(8):737–745.
  4.  Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of 
atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 
2000;43(4):649–655.
  5.  Williams H, Stewart A, von M, Cookson W, Anderson H. Is 
eczema really on the increase worldwide? J Allergy Clin Immun. 
2008;121(4):947–954.
  6.  Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy 
Clin Immunol. 2003;112(6 Suppl):S118–127.
  7.  Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common 
loss-of-function variants of the epidermal barrier protein filaggrin are a major 
predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441–446.
  8.  Weidinger S, O’Sullivan M, Illig T, et al. Filaggrin mutations, atopic 
eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 
2008;121(5):1203–1209 e1201.
Table 5 Long-term treatment trials for atopic eczema
Author Duration No patients Endpoint Treatment arms
Berth-Jones52 16 weeks, randomized 
placebo controlled
295 Flares Fluticasone/placebo 2 days a week
Hanifin52 16 weeks, randomized 
placebo controlled
348 Flares Fluticasone/placebo 4 days a week
Breneman53 52 weeks, randomized, 
placebo controlled.
197 Onset	of	1st	flare Tacrolimus/placebo 3 days a week
Paller54 40 weeks, randomized, 
placebo controlled
105 Disease-free days Tacrolimus/placebo 3 days a week
wollenberg55 52 weeks, randomized 
placebo controlled
224 Onset	of	1st	flare Tacrolimus/placebo 2 days a week
Thaci56 52 weeks, randomized, 
placebo controlled.
250 Onset	of	1st	flare Tacrolimus/placebo 2 days a weekClinical, Cosmetic and Investigational Dermatology 2009:2 92
Spergel Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  9.  Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–1494.
10.  Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality 
in atopic dermatitis: outside-inside-outside pathogenic mechanisms. 
J Allergy Clin Immunol. 2008;121(6):1337–1343.
11.  Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair 
lipids alleviate childhood atopic dermatitis: changes in barrier function 
provide a sensitive indicator of disease activity. J Am Acad Dermatol. 
2002;47(2):198–208.
12.  Bacharier LB, Geha RS. Molecular mechanisms of IgE regulation. 
J Allergy Clin Immunol. 2000;105(2 Pt 2):S547–S558.
13.  Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine 
gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 
1994;94:870–876.
14.  Hamid Q, Naseer T, Minshall E, Song Y, Boguniewicz M, Leung D. 
In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy 
Clin Immunol. 1996;98:225–231.
15.  Leung DYM. Atopic dermatitis: New insights and opportunities 
for therapeutic intervention. J Allergy Clin Immuno. 2000;105(5): 
860–876.
16.  Akdis M, Blaser K, Akdis CA. T regulatory cells in allergy: novel 
concepts in the pathogenesis, prevention, and treatment of allergic 
diseases. J Allergy Clin Immunol. 2005;116(5):961–968; quiz 969.
17.  Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic 
dermatitis in children and adults: European Academy of Allergology 
and Clinical Immunology/American Academy of Allergy, Asthma and 
Immunology/PRACTALL Consensus Report. Allergy. 2006;61(8): 
969–987.
18.  Werfel T, Breuer K. Role of food allergy in atopic dermatitis. Curr 
Opin Allergy Clin Immunol. 2004;4(5):379–385.
19.  Eigenmann PA, Sicherer SH, Borkowski TA, Cohen BA, Sampson HA. 
Prevalence of IgE-mediated food allergy among children with atopic 
dermatitis. Pediatrics. 1998;101(3):E8.
20.  Sicherer SH, Sampson HA. Food hypersensitivity and atopic dermatitis: 
pathophysiology, epidemiology, diagnosis, and management. J Allergy 
Clin Immunol. 1999;104(3 Pt 2):S114–S122.
21.  Lever R, MacDonald C, Waugh P, Aitchison T. Randomised controlled trial 
of advice on an egg exclusion diet in young children with atopic eczema 
and sensitivity to eggs. Pediatr Allergy Immunol. 1998;9(1):13–19.
22.  Woodmansee DP, Christiansen SC. Improvement in atopic dermatitis 
in infants with the introduction of an elemental formula. J Allergy Clin 
Immunol. 2001;108(2):309.
23.  Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B. 
Epidemiology, clinical features, and immunology of the “intrinsic” 
(non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). 
Allergy. 2001;56(9):841–849.
24.  Wang IJ, Lin YT, Yang YH, et al. Correlation between age and 
allergens in pediatric atopic dermatitis. Ann Allergy Asthma Immunol. 
2004;93(4):334–338.
25.  Tuft L, Heck VM. Studies in atopic dermatitis. IV. Importance 
of seasonal inhalant allergens, especially ragweed. J Allergy. 
1952;23(6):528–540.
26.  Tupker RA, De Monchy JG, Coenraads PJ, Homan A, van der Meer JB. 
Induction of atopic dermatitis by inhalation of house dust mite. J Allergy 
Clin Immunol. 1996;97(5):1064–1070.
27.  Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic 
dermatitis: an updated practice parameter. Joint Task Force on Practice 
Parameters. Ann Allergy Asthma Immunol. 2004;93(3 Suppl 2):
S1–S21.
28.  Hughes J, Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5): 
715–721.
29.  Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects 
of topical steroids in daily management of atopic dermatitis. Br J 
Dermatol. 2003;148(1):128–133.
30.  Bode HH. Dwarfism following long-term topical corticosteroid therapy. 
JAMA. 1980;244(8):813–814.
31.  Hill CJ, Rostenberg A Jr. Adverse effects from topical steroids. Cutis. 
1978;21(5):624–628.
32.  Rao VU, Apter AJ. Steroid phobia and adherence – problems, solutions, 
impact on benefit/risk profile. Immunol Allergy Clin North Am. 
2005;25(3):581–595.
33.  FDA. Elidel 1% Cream (Pimecrolimus): Packet Insert. Washington 
DC: Federal Drug Adminstration; 2001.
34.  Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for 
atopic dermatitis: a phase I study in adults and children. J Am Acad 
Dermatol. 1998;38(1):69–76.
35.  Spergel JM. Immunology and treatment of atopic dermatitis. Am J Clin 
Dermatol. 2008;9(4):233–244.
36.  Hultsch T, Kapp A, Spergel J. Immunomodulation and safety of 
topical calcineurin inhibitors for the treatment of atopic dermatitis. 
Dermatology. 2005;211(2):174–187.
37.  Eichenfield LF, Thaci D, de Prost Y, Puig L, Paul C. Clinical man-
agement of atopic eczema with pimecrolimus cream 1% (Elidel) in 
paediatric patients. Dermatology. 2007;215 Suppl 1:3–17.
38.  Meurer M, Lubbe J, Kapp A, Schneider D. The role of pimecrolimus 
cream 1% (Elidel)) in managing adult atopic eczema. Dermatology. 
2007;215 Suppl 1:18–26.
39.  Kapp A, Papp K, Bingham A, et al. Long-term management of 
atopic dermatitis in infants with topical pimecrolimus, a nonsteroid 
anti-inflammatory drug. J Allergy Clin Immun. 2002;110(2): 
277–284.
40.  Hanifin J, Thurston M, Omoto M, Cherill R, Tofte S, Graeber M. 
The eczema area and severity index (EASI): assessment of reliability 
in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001; 
10(1):11–18.
41.  Eichenfield L, Lucky A, Boguniewicz M, et al. Safety and efficacy 
of pimecrolimus (ASM 981) cream 1% in the treatment of mild and 
moderate atopic dermatitis in children and adolescents. J Am Acad 
Dermatol. 2002;46(4):495–504.
42.  Ho V, Gupta A, Kaufmann R, Todd G, Vanaclocha F, Takaoka R, 
Folster-Holst R, Potter P, Marshall K, Thurston M, Bush C, Cherill R. 
Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment 
of atopic dermatitis in infants. J Pediatr. 2003;142:155–162.
43.  Meurer M, Lubbe J, Kapp A, Schneider D. The role of pimecrolimus 
cream 1% (Elidel) in managing adult atopic eczema. Dermatology. 
2007;215(1):18–26.
44.  Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of 
pimecrolimus cream in the long-term management of atopic dermatitis 
in children. Pediatrics. 2002;110(1 Pt 1):e2.
45.  Papp K, Werfel T, Folster-Holst R, et al. Long-term control of atopic 
dermatitis with pimecrolimus cream 1% in infants and young children: 
a two-year study. J Am Acad Dermatol. 2005;52:240–246.
46.  Hanrahan J, Choo P, Carlson W, Greineder D, Faich G, Platt R. 
Terfenadine associated ventricular arrhythmias and QTc prolongation. 
Ann Epidemiol. 1995;5(3):201–209.
47.  Meurer M, Fartasch M, Albrecht G, et al; For The CASM-DE. Study 
Group: Long-term efficacy and safety of pimecrolimus cream 1% 
in adults with moderate atopic dermatitis. Dermatology. 2004;208: 
365–372.
48.  Kaufmann R, Bieber T, Helgesen AL, et al. Onset of pruritus relief 
with pimecrolimus cream 1% in adult patients with atopic dermatitis: 
a randomized trial. Allergy. 2006;61:375–381.
49.  Lubbe J, Degreef H, Hofmann H, et al. Clinical use of pimecrolimus 
cream in atopic eczema: A 6-month open-label trial in 947 patients. 
J Eur Acad Dermatol Venerol. 2003;17(3):183 (abstr 182.139).
50.  Papp K, Staab D, Harper J, et al. Effect of pimecrolimus cream 1% 
on the long-term course of pediatric atopic dermatitis. Int J Dermatol. 
2004;43:978–983.
51.  Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone 
propionate cream for reducing the risk of relapse in atopic dermatitis 
patients. Br J Dermatol. 2002;147(3):528–537.
52.  Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone 
propionate added to emollient maintenance treatment to reduce risk of 
relapse in atopic dermatitis: randomised, double blind, parallel group 
study. BMJ. 2003;326(7403):1367.Clinical, Cosmetic and Investigational Dermatology 2009:2
Clinical, Cosmetic and Investigational Dermatology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal
Clinical, Cosmetic and Investigational Dermatology is an interna-
tional, peer-reviewed, open access, online journal that focuses on 
the latest clinical and experimental research in all aspects of skin 
disease and cosmetic interventions. All areas of dermatology will 
be covered; contributions will be welcomed from all clinicians and 
basic science researchers globally. This journal is indexed on CAS. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
93
Treatment of atopic eczema with pimecrolimus Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53.  Breneman D, Fleischer AB Jr, Abramovits W, et al. Intermittent therapy 
for flare prevention and long-term disease control in stabilized atopic 
dermatitis: a randomized comparison of 3-times-weekly applications 
of tacrolimus ointment versus vehicle. J Am Acad Dermatol. 
2008;58(6):990–999.
54.  Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL. 
Three times weekly tacrolimus ointment reduces relapse in stabilized 
atopic dermatitis: a new paradigm for use. Pediatrics. 2008;122(6):
e1210–e1218.
55.  Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of 
atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 
2008;63(6):742–750.
56.  Thaci D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease 
management with 0.03% tacrolimus ointment for children with atopic 
dermatitis: results of a randomized, multicentre, comparative study. 
Br J Dermatol. 2008;159(6):1348–1356.
57.  Bonifazi E, Garofalo L, Pisani V, Meneghini CL. Role of some 
infectious agents in atopic dermatitis. . Acta Derm Venereo. 
1985;114:98–100.
58.  Rystedt I, Strannegard, IL, Strannegard, O. Recurrent viral infections 
in patients with past or present atopic dermatitis. Br J Dermatol. 
1986;114:575–582.
59.  Luger T, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of 
pimecrolimus cream 1% and topical corticosteroids in adults with moderate 
to severe atopic dermatitis. J Dermatolog Treat. 2004;15:1–10.
60.  Paul C, Cork M, Rossi AB, Papp KA, Barbier N, de Prost Y. Safety and 
tolerability of 1% pimecrolimus cream among infants: experience with 
1133 patients treated for up to 2 years. Pediatrics. 2006;117:e118–e128.
61.  Eichenfield L, Thacib T, de Prostc Y, Puigd L, Paule C. Clinical 
Management of Atopic Eczema with Pimecrolimus Cream 1% (Elidel®) 
in Paediatric Patients. Dermatology. 2007;215(1):3–17.
62.  Arellano F, Wentworth CE, Arana A, Fernandez C, Paul CE. Risk of 
lymphoma following exposure to calcineurin inhibitors and topical steroids 
in patients with atopic dermatitis. J Invest Dermatol. 2007;127:808–816.
63.  Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm 
Venereol. 1980;92:44–47.
64.  Gollnick H, Kaufmann R, Stough D, et al. Pimecrolimus cream 1% 
in the long-term management of adult atopic dermatitis: prevention 
of flare progression. A randomized controlled trial. Br J Dermatol. 
2008;158(5):1083–1093.
65.  Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, 
Brautigam M. Pimecrolimus cream in the long-term management 
of atopic dermatitis in adults: a six-month study. Dermatology. 
2002;205(3):271–277.